These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 1366624)
81. Immunotoxins: status and prospects. Spooner RA; Lord JM Trends Biotechnol; 1990 Jul; 8(7):189-93. PubMed ID: 1366624 [TBL] [Abstract][Full Text] [Related]
82. Redesigning nature's poisons to create anti-tumor reagents. Vitetta ES; Fulton RJ; May RD; Till M; Uhr JW Science; 1987 Nov; 238(4830):1098-104. PubMed ID: 3317828 [TBL] [Abstract][Full Text] [Related]
83. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
84. Immunotoxins: a clinical review of their use in the treatment of malignancies. Hertler AA; Frankel AE J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183 [TBL] [Abstract][Full Text] [Related]
85. Immunotoxins, ligand-toxin conjugates and molecular targeting. Soria M Pharmacol Res; 1989; 21 Suppl 2():35-46. PubMed ID: 2698471 [TBL] [Abstract][Full Text] [Related]
86. Immunotoxins in the therapy of cancer: from bench to clinic. Ghetie V; Vitetta E Pharmacol Ther; 1994 Sep; 63(3):209-34. PubMed ID: 7831391 [TBL] [Abstract][Full Text] [Related]
88. Recombinant immunotoxins for cancer therapy. Brinkmann U; Keppler-Hafkemeyer A; Hafkemeyer P Expert Opin Biol Ther; 2001 Jul; 1(4):693-702. PubMed ID: 11727505 [TBL] [Abstract][Full Text] [Related]
89. Immunotoxins and cytokine toxin fusion proteins. Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283 [TBL] [Abstract][Full Text] [Related]
90. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment. Neville DM Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005 [TBL] [Abstract][Full Text] [Related]
91. Recombinant immunotoxins for the treatment of haematological malignancies. Kreitman RJ Expert Opin Biol Ther; 2004 Jul; 4(7):1115-28. PubMed ID: 15268678 [TBL] [Abstract][Full Text] [Related]
92. Therapeutic potential of anticancer immunotoxins. Choudhary S; Mathew M; Verma RS Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052 [TBL] [Abstract][Full Text] [Related]
93. Immunoconjugates and immunotoxins for therapy of solid tumors. Hellström I; Trail P; Siegall C; Firestone R; Hellström KE Cancer Chemother Pharmacol; 1996; 38 Suppl():S35-6. PubMed ID: 8765413 [No Abstract] [Full Text] [Related]
94. [Protein engineering of Pseudomonas exotoxin and its targeting therapy of cancer]. Kondo T Tanpakushitsu Kakusan Koso; 1989 Oct; 34(13):1793-803. PubMed ID: 2513619 [No Abstract] [Full Text] [Related]
95. [Recombinant immunotoxin for cancer therapy: current status and prospective]. Nagata S Tanpakushitsu Kakusan Koso; 2001 Mar; 46(4 Suppl):540-6. PubMed ID: 11268658 [No Abstract] [Full Text] [Related]
96. Recombinant toxins for the treatment of cancer. Kreitman RJ Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470 [TBL] [Abstract][Full Text] [Related]
97. Immunotoxins: is there a clinical value? Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425 [TBL] [Abstract][Full Text] [Related]